FournierABerrinoFClavel-ChapelonF.Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.Breast Cancer Res Treat2008;
107: 103–111.
2.
de VilliersTJHallJEPinkertonJVet al.
Revised global consensus statement on menopausal hormone therapy.Climacteric2016;
19: 313–315.
3.
HodisHNMackWJHendersonVWet al.; ELITE Research Group.
Vascular effects of early versus late postmenopausal treatment with estradiol.N Engl J Med2016;
374: 1221–1231.
4.
MillerVMJenkinsGDBiernackaJMet al.
Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study.Physiol Genomics2016;
48: 33–41.
5.
PanayNFentonA.Bioidentical hormones: what is all the hype about?Climacteric2010;
13: 1–3.
SantoroNBraunsteinGDButtsCLet al.
Compounded bioidentical hormones in endocrinology practice: an Endocrine Society Scientific Statement.J Clin Endocrinol Metab2016;
101: 1318–1343.
8.
SimonJ.What’s new in hormone replacement therapy: focus on transdermal estradiol and micronised progesterone.Climacteric2012; Suppl 1: 3–10.
9.
VinogradovaYCouplandCHippisley-CoxJ.Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the Q Research and CPRD databases. BMJ2019;
364: k4810.
